Bayer Pharmaceuticals Showcases Innovations at 2021 CIFTIS and Partners with Beijing Medical Association to Advance Clinical Research

BEIJING, Sept. 3, 2021 /PRNewswire/ -- During the 2021 China International Fair for Trade in Services (CIFTIS), Bayer, a multinational pharmaceutical company long committed to development in China, actively participated in the Health and Medical Services thematic section, newly established this year, and reached a cooperation agreement with the Beijing Medical Association on a research project concerning the construction model of clinical research wards in Beijing. The two parties will work together to support and advance the development of clinical research wards in Beijing, explore a new model for these facilities, and facilitate the innovative development of public hospitals. Leaders and representatives from relevant departments, including the Beijing Municipal Health Commission and the Beijing Medical Association, attended and witnessed the signing ceremony.

Bayer and Beijing Medical Association Partner on Research Project on the Construction Model of Research Wards in Beijing

A research ward is a facility within qualified hospitals where healthcare professionals conduct clinical research, including clinical trials of drugs and medical devices and clinical application observations of new biomedical technologies. It serves as a vital healthcare resource and scientific and technological infrastructure. This research project takes public hospitals that have already initiated research ward development as its subjects, systematically reviewing and analyzing the current implementation status, summarizing typical experiences from pilot hospitals, and further exploring new models for research ward construction.

President Feng Guosheng of the Beijing Medical Association stated: “The advancement of healthcare standards is inseparable from medical scientific research. Conducted under the guidance of the Beijing Municipal Health Commission and the Beijing Municipal Science and Technology Commission, this project will help support hospitals in improving the quality of clinical research, strengthening their research and innovation capabilities, and promoting the development of research wards. This collaboration between the Beijing Medical Association and Bayer represents an effective initiative by academic institutions and enterprises to jointly drive the innovative development of clinical research.”

This year marks the first time the healthcare services section has been included in the main theme block of CIFTIS. Particularly as the world currently faces major public health challenges, healthcare-related topics have drawn widespread attention. As a global leading pharmaceutical company, Bayer, upholding its mission of "Science For A Better Life" at this year's CIFTIS, focuses on three major therapeutic areas—diabetes, cardiovascular diseases, and oncology—and is showcasing Xarelto.^®、Glucobay^®、Adalat^®and other high-quality medicines widely trusted by patients, as well as the innovative ophthalmic drug Eylea^®and the new prostate cancer drug Nubeqa^®and other key products, thereby continuously providing more and better medications and treatment options to a broad patient population.

Bayer Pharmaceuticals Exhibits at Health and Sanitary Services Special Exhibition of 2021 CIFTIS

“CIFTIS is an important window for China’s opening-up, providing an international platform for multinational enterprises, including Bayer, to showcase, exchange, and collaborate. It also serves as a vital channel for gaining deeper insights into local healthcare needs in China,” said Zhou Xiaolan, Global Executive Vice President of the Pharmaceuticals Division at Bayer AG and President of Bayer China. “Bayer hopes to take this opportunity to further deepen communication and cooperation with Chinese partners, better leverage our strengths and expertise in the healthcare sector, continuously deliver more innovative outcomes to the Chinese people, and consistently contribute to the advancement and implementation of key national strategies such as ‘Healthy China.’”

As one of the first multinational companies to enter China, Bayer has been firmly rooted in the country for over a century. Over the past two decades, Bayer Pharmaceuticals, based in Beijing, has consistently provided high-quality innovative medicines to patients in China, continuously meeting local healthcare needs and helping to improve public health. Looking ahead, Bayer will continue to leverage its expertise, advance innovation and collaboration, and accelerate the introduction of more high-quality and innovative products that meet the health needs of the Chinese people, contributing to a healthier and better life for Chinese society.